JP2019515666A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515666A5 JP2019515666A5 JP2018552794A JP2018552794A JP2019515666A5 JP 2019515666 A5 JP2019515666 A5 JP 2019515666A5 JP 2018552794 A JP2018552794 A JP 2018552794A JP 2018552794 A JP2018552794 A JP 2018552794A JP 2019515666 A5 JP2019515666 A5 JP 2019515666A5
- Authority
- JP
- Japan
- Prior art keywords
- rrs
- vector
- nucleotide sequence
- sequence encoding
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 226
- 239000002773 nucleotide Substances 0.000 claims description 123
- 125000003729 nucleotide group Chemical group 0.000 claims description 123
- 108020004707 nucleic acids Proteins 0.000 claims description 85
- 102000039446 nucleic acids Human genes 0.000 claims description 85
- 150000007523 nucleic acids Chemical class 0.000 claims description 85
- 210000004027 cell Anatomy 0.000 claims description 71
- 102100030355 Host cell factor 1 Human genes 0.000 claims description 62
- 239000003550 marker Substances 0.000 claims description 59
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 102000025171 antigen binding proteins Human genes 0.000 claims description 29
- 108091000831 antigen binding proteins Proteins 0.000 claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 208000005229 Autosomal recessive Robinow syndrome Diseases 0.000 claims description 16
- 230000002708 enhancing effect Effects 0.000 claims description 16
- 238000001945 resonance Rayleigh scattering spectroscopy Methods 0.000 claims description 16
- 102000018120 Recombinases Human genes 0.000 claims description 8
- 108010091086 Recombinases Proteins 0.000 claims description 8
- 108020004705 Codon Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 108700026220 vif Genes Proteins 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 230000010354 integration Effects 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021114374A JP2021164479A (ja) | 2016-04-20 | 2021-07-09 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
| JP2023201924A JP7781128B2 (ja) | 2016-04-20 | 2023-11-29 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325400P | 2016-04-20 | 2016-04-20 | |
| US62/325,400 | 2016-04-20 | ||
| PCT/US2017/028555 WO2017184832A1 (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of expression-enhancing loci |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114374A Division JP2021164479A (ja) | 2016-04-20 | 2021-07-09 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515666A JP2019515666A (ja) | 2019-06-13 |
| JP2019515666A5 true JP2019515666A5 (OSRAM) | 2020-05-28 |
| JP7096770B2 JP7096770B2 (ja) | 2022-07-06 |
Family
ID=58701851
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552794A Active JP7096770B2 (ja) | 2016-04-20 | 2017-04-20 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
| JP2021114374A Pending JP2021164479A (ja) | 2016-04-20 | 2021-07-09 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
| JP2023201924A Active JP7781128B2 (ja) | 2016-04-20 | 2023-11-29 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114374A Pending JP2021164479A (ja) | 2016-04-20 | 2021-07-09 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
| JP2023201924A Active JP7781128B2 (ja) | 2016-04-20 | 2023-11-29 | 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11512144B2 (OSRAM) |
| EP (1) | EP3445781A1 (OSRAM) |
| JP (3) | JP7096770B2 (OSRAM) |
| KR (2) | KR20230098361A (OSRAM) |
| CN (2) | CN109195986B (OSRAM) |
| AR (1) | AR109451A1 (OSRAM) |
| AU (2) | AU2017253241B2 (OSRAM) |
| BR (1) | BR112018071283A2 (OSRAM) |
| CA (1) | CA3015389A1 (OSRAM) |
| EA (1) | EA201892010A1 (OSRAM) |
| IL (2) | IL314779A (OSRAM) |
| MX (2) | MX2018012868A (OSRAM) |
| SG (2) | SG10202010155YA (OSRAM) |
| TW (2) | TW202415767A (OSRAM) |
| WO (1) | WO2017184832A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202010155YA (en) * | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| IL275462B1 (en) * | 2017-12-22 | 2025-09-01 | Genentech Inc | Targeted integration of nucleic acids |
| CA3123448A1 (en) * | 2018-12-21 | 2020-06-25 | Genentech, Inc. | Targeted integration of nucleic acids |
| TWI851703B (zh) * | 2019-04-02 | 2024-08-11 | 日商中外製藥股份有限公司 | 標的特異性外源基因的導入方法 |
| JP7720787B2 (ja) * | 2019-06-26 | 2025-08-08 | ジェネンテック， インコーポレイテッド | 核酸のランダム化された構成標的化組込み |
| EP4419698A1 (en) | 2021-10-18 | 2024-08-28 | Regeneron Pharmaceuticals, Inc. | Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites |
| AU2022373653A1 (en) | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| TW202330926A (zh) | 2021-10-18 | 2023-08-01 | 美商再生元醫藥公司 | 聚核苷酸之受控制轉錄 |
| WO2023122246A1 (en) * | 2021-12-22 | 2023-06-29 | Genentech, Inc. | Multi-vector recombinase mediated cassette exchange |
| JPWO2023238949A1 (OSRAM) * | 2022-06-10 | 2023-12-14 | ||
| WO2025054526A1 (en) | 2023-09-07 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Production and purification of covalently surface modified adeno-associated virus |
| WO2025111473A1 (en) | 2023-11-21 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
| JP4817657B2 (ja) | 2002-05-29 | 2011-11-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 誘導性の真核生物発現システム |
| WO2004046340A2 (en) | 2002-11-14 | 2004-06-03 | Genentech, Inc. | Intron fusion construct and method of using for selecting high-expressing production cell lines |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| WO2008079943A2 (en) | 2006-12-21 | 2008-07-03 | Smithkline Beecham Corporation | Novel methods |
| US20080216185A1 (en) | 2007-01-19 | 2008-09-04 | Invitrogen Corporation | Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines |
| ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| US7771997B2 (en) | 2007-06-04 | 2010-08-10 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| CN102459603B (zh) * | 2009-06-02 | 2013-11-06 | 瑞泽恩制药公司 | 岩藻糖基化缺陷型细胞 |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| JP6091894B2 (ja) | 2009-09-16 | 2017-03-15 | ジェネンテック， インコーポレイテッド | コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用 |
| SG178940A1 (en) * | 2009-09-18 | 2012-04-27 | Selexis Sa | Products and methods for enhanced transgene expression and processing |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| JP5997154B2 (ja) | 2010-08-16 | 2016-09-28 | ノビミューン エスアー | 多重特異性多価抗体の生成方法 |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) * | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI745610B (zh) | 2012-11-14 | 2021-11-11 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| AU2015335921B2 (en) | 2014-10-23 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Novel CHO integration sites and uses thereof |
| PT3353212T (pt) | 2015-09-23 | 2022-01-05 | Regeneron Pharma | Anticorpos biespecíficos anti-cd3 otimizados e suas utilizações |
| SG10202010155YA (en) * | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
-
2017
- 2017-04-20 SG SG10202010155YA patent/SG10202010155YA/en unknown
- 2017-04-20 KR KR1020237020953A patent/KR20230098361A/ko active Pending
- 2017-04-20 IL IL314779A patent/IL314779A/en unknown
- 2017-04-20 AU AU2017253241A patent/AU2017253241B2/en active Active
- 2017-04-20 MX MX2018012868A patent/MX2018012868A/es unknown
- 2017-04-20 JP JP2018552794A patent/JP7096770B2/ja active Active
- 2017-04-20 IL IL262266A patent/IL262266B2/en unknown
- 2017-04-20 CA CA3015389A patent/CA3015389A1/en active Pending
- 2017-04-20 WO PCT/US2017/028555 patent/WO2017184832A1/en not_active Ceased
- 2017-04-20 US US16/095,084 patent/US11512144B2/en active Active
- 2017-04-20 BR BR112018071283A patent/BR112018071283A2/pt unknown
- 2017-04-20 SG SG11201807885PA patent/SG11201807885PA/en unknown
- 2017-04-20 AR ARP170101019A patent/AR109451A1/es unknown
- 2017-04-20 TW TW112130927A patent/TW202415767A/zh unknown
- 2017-04-20 CN CN201780024557.0A patent/CN109195986B/zh active Active
- 2017-04-20 EP EP17723183.4A patent/EP3445781A1/en active Pending
- 2017-04-20 CN CN202211606177.7A patent/CN116515757A/zh active Pending
- 2017-04-20 TW TW106113298A patent/TWI827531B/zh active
- 2017-04-20 EA EA201892010A patent/EA201892010A1/ru unknown
- 2017-04-20 KR KR1020187029365A patent/KR102547738B1/ko active Active
-
2018
- 2018-10-19 MX MX2025003852A patent/MX2025003852A/es unknown
-
2021
- 2021-07-09 JP JP2021114374A patent/JP2021164479A/ja active Pending
-
2022
- 2022-09-28 US US17/936,059 patent/US20230130799A1/en active Pending
-
2023
- 2023-11-29 JP JP2023201924A patent/JP7781128B2/ja active Active
-
2024
- 2024-09-26 AU AU2024220124A patent/AU2024220124A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515666A5 (OSRAM) | ||
| JP2019514358A5 (OSRAM) | ||
| JP2021087433A5 (OSRAM) | ||
| JP2006515520A5 (OSRAM) | ||
| ES2909150T3 (es) | Composiciones y colecciones que comprenden receptores de células T recombinantes y procedimientos de uso de receptores de células t recombinantes | |
| JP2019150066A5 (OSRAM) | ||
| SA519401562B1 (ar) | بروتينات دمج FC دايمرية غير متجانسة لـ IL15/IL15Rα | |
| JP2020503885A5 (OSRAM) | ||
| Dodd et al. | Therapeutic monoclonal antibodies to complex membrane protein targets: antigen generation and antibody discovery strategies | |
| JP2020501516A5 (OSRAM) | ||
| JP2018533963A5 (OSRAM) | ||
| RU2011129459A (ru) | Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение | |
| RU2014118869A (ru) | Мыши с ограниченной тяжелой цепью иммуноглобулина | |
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| HK1207575A1 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
| JP2015519055A5 (OSRAM) | ||
| JP2011504721A5 (OSRAM) | ||
| JP2018525007A (ja) | 免疫グロブリンの産生増強 | |
| EP2502934A1 (en) | Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds | |
| JP2015518479A5 (OSRAM) | ||
| JP2013532974A5 (OSRAM) | ||
| RU2014153673A (ru) | Гуманизированные не относящиеся к человеку животные с ограниченными локусами тяжелой цепи иммуноглобулина | |
| JP2017537621A5 (OSRAM) | ||
| Sarkar et al. | Nonself recognition is mediated by HET‐C heterocomplex formation during vegetative incompatibility | |
| JPWO2020097393A5 (OSRAM) |